Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial
Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial
复制标题
DOI：
10.1016/j.drugalcdep.2008.08.006
复制
发表时间：
2009-01-01
影响因子：
4.2
通讯作者：
Rosenblum, Andrew
中科院分区：
文献类型：
--
作者：
Magura, Stephen;Lee, Joshua D.;Rosenblum, Andrew
丁丙诺啡很少在矫正环境中作为阿片类激动剂维持治疗给药。这项研究介绍了丁丙诺啡的维护在一个大型城市监狱，赖克斯岛在纽约市。没有参加社区美沙酮治疗并被判处10-90天监禁的英雄独立男性（N=116）自愿随机分配到丁丙诺啡或美沙酮维持治疗，后者是里克斯岛符合条件的囚犯的护理标准。在监狱中，丁丙诺啡和美沙酮维持治疗的完成率同样高，但丁丙诺啡组报告在社区中接受指定的释放后治疗的频率明显高于美沙酮组（48%对14%，p
Buprenorphine has rarely been administered as an opioid agonist maintenance therapy in a correctional setting. This study introduced buprenorphine maintenance in a large urban jail, Rikers Island in New York City. Hero in-dependent men not enrolled in community methadone treatment and sentenced to 10-90 days in jail (N=116) were voluntarily randomly assigned either to buprenorphine or methadone maintenance, the latter being the standard of care for eligible inmates at Rikers. Boprenorphine and methadone maintenance completion rates in jail were equally high, but the buprenorphine group reported for their designated post-release treatment in the community significantly more often than did the methadone group (48% vs. 14%, p